(Refiles to change word "to" to lower case in headline, with no
change to text)
By Andreas Kröner
FRANKFURT May 12 The head of German healthcare
group Fresenius SE said he would abstain from the
takeover market for now, after striking three deals worth
billions of euros in total since taking over less than a year
"First we should properly chew and also digest what we have
bitten off," Chief Executive Stephan Sturm told shareholders at
the group's annual general meeting on Friday.
"And if all that goes according to our expectations, and
it's also very savoury, then we will push for a possible use of
our existing war chest," he added.
Fresenius last month stepped up its dealmaking, agreeing to
buy U.S. generic drugmaker Akorn Inc for $4.75 billion
and the biosimilars arm of Germany's Merck KGaA for as much as
670 million euros.
It has also bought Spanish hospital chain Quironsalud for
5.8 billion euros ($6.31 billion).
($1 = 0.9199 euros)
(Writing by Ludwig Burger; Editing by Maria Sheahan)